Carcinologic Speech Severity Index

Head and Neck Cancer Clinical Trial

— C2SI  

Official title:

A Speech Disorders Severity Index to Measure the Impact of Oral and Pharyngeal Cavity on Speech Production

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02875795
• Other study ID #: 14 7414 07
• Status: Completed
• Phase: N/A
• Start date: January 1, 2015
• Est. completion date: December 31, 2017

Study information

• Verified date: July 2020
• Source: University Hospital, Toulouse
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The hypothesis of the present study is that an automatic assessment technic can measure the impact of the speech disorders on the communication abilities giving a severity index of speech in patients treated for head and neck and particularly for oral and pharyngeal cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 124
• Est. completion date: December 31, 2017
• Est. primary completion date: December 31, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Oral and Pharyngeal cancer T2 to T4 for having a wide dynamic of deficit

• Treatment by surgery and/or radiotherapy and/or chemotherapy

• Delay after the end of the treatment of minimum 6 months.

Exclusion Criteria:

• Patients with a previous speech disorders (ie stuttering… )

• Patients not able to perform the whole task

Related Conditions & MeSH terms

• Head and Neck Cancer
• Head and Neck Neoplasms

Intervention

Procedure:
• automatic speech processing tool

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Toulouse	University Jean-Jaures, Toulouse, France

References & Publications (1)

Balaguer M, Boisguérin A, Galtier A, Gaillard N, Puech M, Woisard V. Assessment of impairment of intelligibility and of speech signal after oral cavity and oropharynx cancer. Eur Ann Otorhinolaryngol Head Neck Dis. 2019 Oct;136(5):355-359. doi: 10.1016/j. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	carcinologic speech severity index	The main objective is to demonstrate that the carcinologic speech severity index (C2SI), obtained by an automatic speech processing tool, produces equivalent or superior outcomes than a score of speech intelligibility obtained by human listeners, in terms of quality of life foreseeing the speech handicap, after the treatment of oral and/or pharyngeal cancer.	day 0